Skip to main content
Shanghai Junshi Biosciences Co., Ltd. logo

Shanghai Junshi Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 1877 ISIN · CNE100003FF7 HKEX Manufacturing
Open in API
Filings indexed 1,731 across all filing types
Latest filing 2026-04-21 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 1877

About Shanghai Junshi Biosciences Co., Ltd.

http://www.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company established in 2012. It is dedicated to the discovery, development, clinical research, and commercialization of innovative therapeutics, prioritizing the creation of first-in-class and best-in-class drugs. The company utilizes a global integrated R&D system and proprietary full life cycle antibody development platform technology to build a diversified and complementary pipeline. Junshi Biosciences operates as a full-chain entity, integrating research, production, and commercialization capabilities to maintain global competitiveness in the biopharmaceutical sector.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The text is a brief notice (242 characters) stating that an announcement has been published elsewhere. There is no substantive financial content or report itself provided, only an announcement of publication. This matches a Report Publication Announcement (RPA) under the 'menu vs meal' rule.
2026-04-21 English
OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE ADDITION OF IMPLEMENTING ENTITY OF CERTAIN SUB-PROJECTS UNDER THE INVESTMENT PROJECTS
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Junshi Biosciences Co., Ltd. regarding the addition of an implementing entity for certain sub-projects under investment projects funded by proceeds from a 2022 share issuance. It details the background of the proceeds, the investment projects, the new implementing entity, and the board's approval. The document references regulatory rules and verification opinions but does not contain financial statements or detailed financial performance data. It is a regulatory announcement about changes in the use of proceeds and project implementation entities, not a full financial report or earnings release. The document is over 13,000 characters, so it is not a brief report publication announcement. It fits best as a Capital/Financing Update (CAP) because it relates to the use of proceeds from a capital raise and changes in project implementation funded by that capital.
2026-04-21 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 86% confidence The document is a formal announcement by Shanghai Junshi Biosciences that the Board will meet on 27 April 2026 to consider and approve the unaudited quarterly results. It does not contain the results themselves but announces the timing of the upcoming report approval. This aligns with the definition of a Report Publication Announcement (RPA).
2026-04-15 English
OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE EXPIRATION OF THE PLAN FOR THE REDUCTION IN SHAREHOLDING OF THE SHAREHOLDERS HOLDING MORE THAN 5% OF THE S
Major Shareholding Notification Classification · 82% confidence The document is an official stock exchange announcement about a plan by a >5% shareholder to reduce holdings and the fact that the plan expired without any shares being sold. It contains shareholding percentages, reduction period, and results of the reduction plan. This matches the “Major Shareholding Notification” category (MRQ) for disclosures regarding significant shareholders’ holdings and changes (or non‐changes).
2026-04-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 85% confidence The document is a mandatory monthly return (Form FF301) submitted to the Hong Kong Stock Exchange under Chapter 19B of the Listing Rules, detailing movements in authorized/issued share capital, share options, and public float confirmations. It is not presenting an AGM package, earnings release, annual or interim report, or any of the defined transactional filings (e.g., M&A, delisting, insider dealing), nor is it an announcement that a separate report has been published. It is a routine regulatory submission providing corporate share movement data and thus falls under the general “Regulatory Filings” category.
2026-04-02 English
OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RESULTS OF THE SHAREHOLDING INCREASE AND CHANGE IN EQUITY OF ONE OF THE CONTROLLING SHAREHOLDERS, ACTUAL C
Major Shareholding Notification Classification · 98% confidence The document is an issuer announcement under HKEX Listing Rule 13.10B detailing the completion of a shareholding increase plan by Mr. Xiong Jun (a controlling shareholder/director) and the resulting change in equity, which crosses the 1% threshold. It is not a report publication notice, not a company buy-back, nor a dividend or financing update. It matches the definition of a Major Shareholding Notification (changes in significant share ownership/threshold crossings).
2026-03-31 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.